Completed Grants and Sponsored Research
Sponsoring Organization: Gradalis Inc.
Pilot Study for ctDNA Analysis
Description of Major GoalsThe goal of this project is to detect circulating tumor DNA levels in patients with Ewing sarcoma who were enrolled on a phase I study and correlate levels with treatment responses.
Sponsoring Organization: SARC Demonstration Project
Development of a Circulating Tumor DNA Assay for Leiomyosarcoma
Description of Major GoalsThe goal of this project is to detect circulating tumor DNA levels in patients with leiomyosarcoma who were enrolled on a multi-institutional prospective trial and determine whether levels correspond to outcomes.
Sponsoring Organization: Pediatric Cancer Research Foundation
Development of Circulating Tumor DNA Assays for Translocation Positive Sarcomas
Description of Major GoalsThe major goal of this project is to validate the measurement of circulating tumor DNA assays (also known as liquid biopsies) obtained from blood samples as a biomarker of poor outcome for patients with Ewing sarcoma. We believe the results of this study could radically change the way we treat patients with the most aggressive form of this disease.
Sponsoring Organization: Boston Children's Hospital Translational research Program
Development of Circulating Tumor DNA Assays for Ewing Sarcomas
Description of Major GoalsIn this proposal, we aim to validate a new assay that detects tumor DNA from peripheral blood draws as a surrogate for tumor burden.
Sponsoring Organization: St. Baldrick's Foundation
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma
Description of Major GoalsThe major goals of this project are to perform preclinical testing of FAK inhibition using in vivo models of tumor progression and metastasis, to determine effective combinations of therapy with FAK inhibition in the treatment of Ewing sarcoma, and to determine which integrins are necessary for growth, transformation, and FAK activation in Ewing sarcoma.
Sponsoring Organization: Children's Oncology Group
Prognostic significance of STAG2 loss and TP53 mutations in Ewing sarcoma
Description of Major GoalsThe aims of this project are: (1) Does STAG2 and TP53 immunohistochemical staining successfully identify tumors with deleterious mutations in these genes? (2) Is STAG2 loss, alone or in combination with TP53 alteration, predictive of poor outcome inpatients with localized disease? (3) Does STAG2 loss occur more commonly in patients who present with metastatic disease?
Sponsoring Organization: Go4TheGoal Foundation
Development of Circulating Tumor DNA Assays for Translocation Positive Sarcomas
Description of Major GoalsThe major goals of this project are to validate TranSS-Seq assay for detection of targeted sarcoma translocations in patient plasma; to correlate tumor-derived cfDNA level at diagnosis with outcome in cases of translocation-positive pediatric sarcomas; to correlate tumor-derived cfDNA levels over time with clinical course in translocationpositive pediatric sarcomas.
Sponsoring Organization: Pediatric Cancer Research Foundation
Bridging the gap between target discovery and clinical trials in pediatric Ewing sarcoma
Description of Major GoalsThe major goals of this project are to perform the preclinical studies necessary to validate the use of FAK inhibition as a therapeutic approach to prevent disease progression and metastasis. Our approach will include testing the use of anti-Ewing chemotherapy and other targeted agents in combination with FAK inhibition to identify the most promising combinations. We also will utilize a genetic screening approach to find new therapeutic targets that may cooperate with FAK activity in Ewing sarcoma.
Sponsoring Organization: Pediatric Cancer Research Foundation
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma
Description of Major GoalsThe major goals of this project are to complete the necessary preclinical studies to bring a FAK inhibitor to clinical trials for children with Ewing sarcoma; to determine if there is a role for this treatment approach in the prevention of metastatic disease; to nominate synergistic therapeutic combinations for future trials, and to identify additional adhesion molecules that play a role in the pathogenesis of Ewing sarcoma and activate FAK.
Sponsoring Organization: Bear Necessities Pediatric Cancer Foundation
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma
Description of Major GoalsThe major goals of this project are to perform preclinical testing of FAK inhibition using in vivo models of tumor progression and metastasis, to determine effective combinations of therapy with FAK inhibition in the treatment of Ewing sarcoma, and to determine which integrins are necessary for growth, transformation, and FAK activation in Ewing sarcoma.